Drug Updates

Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis

Although psoriatic arthritis most often affects the distal joints in the fingers and toes, the disease can also affect the lower back, wrists, knees, and ankles.

Read More ›

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis
Patients with psoriasis are at increased risk for psoriatic arthritis, heart disease, stroke, hypertension, type 2 diabetes, metabolic syndrome, eye disorders, and obesity, as well as for other autoimmune diseases (eg, celiac disease, Crohn’s disease), Parkinson’s disease, and kidney disease. Read More ›


Psoriasis, the most prevalent autoimmune disease in the United States, affects approximately 7.5 million people. Read More ›

Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015. Overall, 61% of women with breast cancer are diagnosed while the disease is confined to the breast; for these women, the 5-year survival rate is 98.6%. However, for women with metastatic breast cancer, the 5-year survival rate falls sharply, to 26%. Read More ›

Multiple myeloma, also referred to as myeloma, is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 26,800 new cases of multiple myeloma will be diagnosed in 2015, and 11,240 deaths will be attributed to this disease. Read More ›

Similar to myelofibrosis and essential thrombocythemia, polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm. Polycythemia vera is characterized by the clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Increased red blood cell mass results in the hyperviscosity of the blood, an increased risk for thrombosis, poor quality of life, and a shortened life expectancy. Read More ›

One of the most fear-inducing side effects of chemotherapy is nausea and vomiting. Without appropriate antiemetic prophylaxis, 70% to 80% of all patients with cancer who receive chemotherapy experience nausea and/or vomiting. Read More ›

Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the 2015 National Comprehensive Cancer Network (NCCN) conference, the newer drug, pazopanib, may have some advantage in terms of total cost of care, but survival outcomes were exactly the same. Read More ›

Thyroid cancer, cancer that starts in the thyroid gland, accounts for 3.8% of all cancer cases in the United States. There were an estimated 62,980 new cases of thyroid cancer and 1890 deaths resulting from thyroid cancer in 2014. Thyroid cancer is most common in people aged 45 to 54 years (median age, 50 years), and it occurs 2 to 3 times more often in women than in men. The incidence of thyroid cancer has risen steadily in recent years. Although this increasing rate can be attributed largely to disease detection at an earlier stage, the incidence of larger tumors has also increased. Read More ›

Page 1 of 3

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication